Osimertinib-d6 - ≥99% , CAS No.1638281-44-3

CAS: 1638281-44-3 Cat. No.: O646850 Fórmula: C28H27D6N7O2 Peso molecular: 505.64
Disponível para encomenda
GRAU & PUREZA ≥99%
Storage
Store at 2-8°C,Protected from light,Argon charged
Shipped In
Wet ice
★
Tamanho
USA
Alemanha (EU)*
Preço
Qtd
1mg
O646850-1mg
Sob encomenda · 8–12 semanas
2960,90US$
Enter a quantity for the sizes you want to add.
🧪
Por que este grau

≥99% para fluxos de trabalho cromatográficos e analíticos sensíveis que exigem interferência mínima da linha de base.

🌡

Armazenamento e envio

Store at 2-8°C,Protected from light,Argon charged Envio Wet ice. Consulte o COA específico do lote para obter as especificações exatas.

📋

Documentos de qualidade

SDS, COA, ficha técnica e folha de especificações disponíveis para download. COA específico do lote acessível por meio de pesquisa por número de lote.

📚

Comprovação documental

Citado em 0 publicações revisadas por pares nas áreas de cromatografia, síntese orgânica e reações de acoplamento cruzado.

Visão geral

Osimertinib-d 6 is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

In Vitro

Osimertinib (AZD9291) (0-10 μM; 72 hours) dramatically inhibits cell proliferation with IC 50 s of 41, 26, 41, and 31 nM, respectively. Osimertinib (0-10 μM; 72 hours) inhibits cell proliferation (Ba/F3 cells harboring a T790M mutation, exon 19del+T790M, or L858R+T790M) with IC 50 s of 6, 7, and 74 nM, respectively. Osimertinib (0-10 μM; 72 hours) inhibits Ba/F3 cells harboring EGFR exon 20 insertion mutations (IC 50 ranging from 16-701 nM for A763_Y764insFQEA (FQEA), Y764_V765insHH (HH), A767_V769dupASV (ASV), and D770_N771insNPG (NPG) cells). Osimertinib shows high levels of phenotype potency in both sensitizing-mutant (mean IC 50 of 8 nM in PC-9) and T790M (mean IC 50 of 11 and 40 nM in H1975 and PC-9VanR respectively) EGFR cell lines. Osimertinib has much less activity towards wild-type EGFR (mean IC 50 of 650 and 461 nM in Calu3 and H2073 respectively). Osimertinib (0.1 μM; 48 hours) induces apoptosis in Ba/F3 cells (apoptosis rate of 40.9% and 90% in EGFR exon 19del+T790M, EGFR L858R+T790M respectively). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: PC-9, H3255, PC-9ER, and H1975 cells Concentration: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 72 hours Result: Dramatically inhibited cell proliferation (IC 50 =41,26, 41, 31 nM, respectively) Cell Proliferation AssayCell Line: Ba/F3 cells (harboring a T790M mutation, exon 19del+T790M, or L858R+T790M) Concentration: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 72 hours Result: Inhibited cell proliferation (IC 50 = 6, 7, 74 nM, respectively) Apoptosis AnalysisCell Line: Ba/F3 cells (harboring EGFR exon 20 insertion mutations) Concentration: 0.0001, 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 72 hours Result: Inhibited cell proliferation (IC 50 = 16, 701, 230, 38 nM, respectively) Apoptosis AnalysisCell Line: Ba/F3 cells(harboring EGFR exon 19del+T790M or EGFR L858R+T790M) Concentration: 0.1 μM Incubation Time: 48 hours Result: Inducted apoptosis with the rate of 40.9% and 90% in EGFR T790M positive mutations cells respectively.

In Vivo

Osimertinib (0.1-25 mg/kg; p.o.; daily for 14 day) induces significant dose-dependent regression in both PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models Dosage: 0.1-10 mg/kg (PC-9 xenograft models); 0.5- 25 mg/kg (H1975 xenograft models) Administration: p.o.; daily for 14 day Result: Induced significant dose-dependent regression in both PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models.

Form:Solid

Especificações

Especificações e pureza
≥99%
Mecanismos bioquímicos e fisiológicos
Osimertinib-d 6 is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated
Condições de armazenamento de armazenamento
Store at 2-8°C,Protected from light,Argon charged
Enviado em
Wet ice
Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.
Tipo de ação
INHIBITOR
Pureza
≥99%
Nomes e identificadores
Sorrisos canónicos
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
IUPAC Name
N-[2-[2-[bis(trideuteriomethyl)amino]ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
InChIKey
DUYJMQONPNNFPI-XERRXZQWSA-N
INCHI
1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)/i2D3,3D3
SMILES isoméricas
[2H]C([2H])([2H])N(CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C)OC)C([2H])([2H])[2H]
Peso molecular
505.64
Reaxy-Rn
23334373
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=23334373&ln=

Documentação

📋 Ficha de dados de segurança (FDS)

Documento abrangente sobre perigos, manuseamento, armazenamento e conformidade regulamentar.

<<<<<<< HEAD Baixar SDS → ======= Baixar SDS → >>>>>>> release248-p3

✅ Certificado de análise (COA)

Dados de qualidade específicos do lote. Introduza o número de lote para obter o COA exato.

Consultar COA →

📊 Ficha técnica

Resumo de referência rápida das especificações e aplicações do produto.

Ver ficha técnica →

🔬 Folha de especificações

Atributos de qualidade completos e critérios de aceitação para este grau.

Ver folha de especificações →

Dados avançados

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassBenzenoids
ClasseBenzene and substituted derivatives
SubclassAnilides
Intermediate Tree Nodes Not available
Direct Parent2'-Aminoanilides
Alternative Parents N-alkylindoles  Aminophenyl ethers  Indoles  Methoxyanilines  Anisoles  Dialkylarylamines  Phenoxy compounds  Methoxybenzenes  N-arylamides  Alkyl aryl ethers  Aminopyrimidines and derivatives  N-methylpyrroles  Heteroaromatic compounds  Acrylic acids and derivatives  Secondary carboxylic acid amides  Amino acids and derivatives  Trialkylamines  Azacyclic compounds  Hydrocarbon derivatives  Carbonyl compounds  Organic oxides  
Molecular FrameworkAromatic heteropolycyclic compounds
Substituents N-alkylindole - 2'-aminoanilide - Indole - Indole or derivatives - Aminophenyl ether - Methoxyaniline - Anisole - Phenoxy compound - Phenol ether - Tertiary aliphatic/aromatic amine - N-arylamide - Dialkylarylamine - Aniline or substituted anilines - Methoxybenzene - Alkyl aryl ether - Aminopyrimidine - N-methylpyrrole - Pyrimidine - Substituted pyrrole - Acrylic acid or derivatives - Heteroaromatic compound - Pyrrole - Carboxamide group - Tertiary aliphatic amine - Amino acid or derivatives - Tertiary amine - Secondary carboxylic acid amide - Carboxylic acid derivative - Ether - Organoheterocyclic compound - Azacycle - Organic oxide - Organic nitrogen compound - Carbonyl group - Organic oxygen compound - Amine - Organonitrogen compound - Organooxygen compound - Hydrocarbon derivative - Aromatic heteropolycyclic compound
DescriçãoThis compound belongs to the class of organic compounds known as 2'-aminoanilides. These are organic compounds containing an anilide moieties that carries an amino group at the 2-position of the benzene ring.
External Descriptors Not available
Estrutura 3D
Modelo de Estrutura Química Interativa





Certificados(CoA,COO,BSE/TSE e Mapa de Análise)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculadoras de soluções
Revisões

Avaliações dos Clientes

Deseja que lhe enviemos uma mensagem quando tivermos descontos disponíveis?

Lembrar-me mais tarde

Obrigado! Por favor, verifique a sua caixa de entrada de e-mail para confirmar.

Ops! As notificações estão desativadas.